VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.